You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBrinzolamide
Accession NumberDB01194  (APRD00475)
TypeSmall Molecule
GroupsApproved
DescriptionBrinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Structure
Thumb
Synonyms
Azopt
Brinzolamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AzoptSuspension / drops10 mg/mLOphthalmicAlcon Laboratories, Inc.1998-04-30Not applicableUs
AzoptSuspension1 %OphthalmicAlcon Canada Inc1998-11-11Not applicableCanada
Sandoz BrinzolamideSuspension1 %OphthalmicSandoz Canada IncorporatedNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AzargaAlcon Canada Inc
SimbrinzaAlcon Laboratories, Inc.
SaltsNot Available
Categories
UNII9451Z89515
CAS number138890-62-7
WeightAverage: 383.507
Monoisotopic: 383.064332867
Chemical FormulaC12H21N3O5S3
InChI KeyHCRKCZRJWPKOAR-JTQLQIEISA-N
InChI
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
IUPAC Name
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1λ⁶-thieno[3,2-e][1,2]thiazine-6-sulfonamide
SMILES
CCN[[email protected]]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Structured Indications
PharmacodynamicsUsed in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinzolamide can decrease intraocular pressure by approximately 16-19% in patients with elevated intraocular pressure.
Mechanism of actionBrinzolamide is a highly specific inhibitor of CA-II, which is the main CA isoenzyme involved in the secretion of aqueous humor. Inhibition of CA in the ciliary process of the eye slows the formation of bicarbonate, and reduces sodium and fluid transport. This results in a reduction in the rate of aqueous humor secretion and the intraocular pressure. Brinzolamide is absorbed systemically following topical ocular administration. Since it has a high affinity for CA-II, brinzolamide binds extensively to red blood cells, where CA-II is primarily found. As sufficient CA-II activity remains, adverse effects resulting from the systemic inhibition of CA by brinzolamide are not observed. The metabolite N-desethyl brinzolamide is also formed. This metabolite binds to CA and accumulates in red blood cells as well. In the presence of brinzolamide, the metabolite binds mainly to carbonic anhydrase I (CA-I).
TargetKindPharmacological actionActionsOrganismUniProt ID
Carbonic anhydrase 2Proteinyes
inhibitor
HumanP00918 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Carbonic anhydrase 4Proteinunknown
inhibitor
HumanP22748 details
Carbonic anhydrase 5A, mitochondrialProteinunknown
inhibitor
HumanP35218 details
Related Articles
AbsorptionAbsorbed into systemic circulation following topical ocular application
Volume of distributionNot Available
Protein bindingApproximately 60%.
Metabolism

Ophthalmic

Route of eliminationNot Available
Half life111 days
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Brinzolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Brinzolamide.Approved, Vet Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Brinzolamide.Approved
AmiodaroneThe serum concentration of Brinzolamide can be increased when it is combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Brinzolamide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Brinzolamide can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Brinzolamide can be decreased when combined with Atomoxetine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Brinzolamide.Approved, Investigational
BexaroteneThe serum concentration of Brinzolamide can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Brinzolamide can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Brinzolamide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Brinzolamide can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Brinzolamide.Approved, Investigational
CeritinibThe serum concentration of Brinzolamide can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe serum concentration of Brinzolamide can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Brinzolamide can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Brinzolamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Brinzolamide can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Brinzolamide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Brinzolamide can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Brinzolamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Brinzolamide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Brinzolamide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Brinzolamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Brinzolamide can be decreased when combined with Delavirdine.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Brinzolamide.Investigational
DexamethasoneThe serum concentration of Brinzolamide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Brinzolamide.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Brinzolamide.Approved
DihydroergotamineThe metabolism of Brinzolamide can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Brinzolamide can be decreased when combined with Diltiazem.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Brinzolamide.Approved
DoxycyclineThe metabolism of Brinzolamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Brinzolamide can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Brinzolamide can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Brinzolamide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Brinzolamide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Brinzolamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Brinzolamide.Withdrawn
EtravirineThe serum concentration of Brinzolamide can be decreased when it is combined with Etravirine.Approved
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Brinzolamide.Approved, Withdrawn
FluconazoleThe metabolism of Brinzolamide can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Brinzolamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Brinzolamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Brinzolamide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Brinzolamide can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Brinzolamide can be increased when it is combined with Fusidic Acid.Approved
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Brinzolamide.Approved, Vet Approved
IdelalisibThe serum concentration of Brinzolamide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Brinzolamide can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of Brinzolamide can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Brinzolamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Brinzolamide can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Brinzolamide can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Brinzolamide can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Brinzolamide can be increased when it is combined with Ketoconazole.Approved, Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Brinzolamide.Approved
LopinavirThe serum concentration of Brinzolamide can be increased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Brinzolamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Brinzolamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Brinzolamide can be increased when combined with Lumacaftor.Approved
MemantineBrinzolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Brinzolamide.Approved
MetforminThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Brinzolamide.Approved
MifepristoneThe serum concentration of Brinzolamide can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Brinzolamide can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Brinzolamide can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Brinzolamide can be decreased when it is combined with Nafcillin.Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Brinzolamide.Investigational
NefazodoneThe serum concentration of Brinzolamide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Brinzolamide can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Brinzolamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Brinzolamide can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Brinzolamide can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Brinzolamide.Investigational
OlaparibThe metabolism of Brinzolamide can be decreased when combined with Olaparib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Brinzolamide.Approved
OsimertinibThe serum concentration of Brinzolamide can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Brinzolamide can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Brinzolamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Brinzolamide can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Brinzolamide can be increased when combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe serum concentration of Brinzolamide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Primidone.Approved, Vet Approved
QuinidineBrinzolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
RanolazineThe metabolism of Brinzolamide can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Brinzolamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Brinzolamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Brinzolamide can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Brinzolamide can be increased when it is combined with Ritonavir.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Brinzolamide.Approved, Vet Approved
SaquinavirThe serum concentration of Brinzolamide can be increased when it is combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Brinzolamide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Brinzolamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Brinzolamide can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Brinzolamide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Brinzolamide can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Brinzolamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Brinzolamide can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Brinzolamide can be increased when it is combined with Telithromycin.Approved
TiclopidineThe metabolism of Brinzolamide can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Brinzolamide can be decreased when it is combined with Tocilizumab.Approved
VenlafaxineThe metabolism of Brinzolamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Brinzolamide can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Brinzolamide can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Brinzolamide can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Alessandro Falchi, Ottorino De Lucchi, Andrea Castellin, “PROCESS FOR THE PREPARATION OF BRINZOLAMIDE.” U.S. Patent US20110118461, issued May 19, 2011.

US20110118461
General References
  1. Ermis SS, Ozturk F, Inan UU: Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification. Eye (Lond). 2005 Mar;19(3):303-7. [PubMed:15258611 ]
  2. Iester M, Altieri M, Michelson G, Vittone P, Traverso CE, Calabria G: Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 2004 Nov-Dec;218(6):390-6. [PubMed:15564757 ]
  3. Kaup M, Plange N, Niegel M, Remky A, Arend O: Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol. 2004 Feb;88(2):257-62. [PubMed:14736787 ]
  4. Iester M: Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008 Sep;2(3):517-23. [PubMed:19668749 ]
  5. DeSantis L: Preclinical overview of brinzolamide. Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29. [PubMed:10665514 ]
External Links
ATC CodesS01EC54S01EC04
AHFS Codes
  • 52:10.00
PDB Entries
FDA labelDownload (580 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9765
Blood Brain Barrier+0.8754
Caco-2 permeable-0.7123
P-glycoprotein substrateSubstrate0.8185
P-glycoprotein inhibitor INon-inhibitor0.6795
P-glycoprotein inhibitor IINon-inhibitor0.9245
Renal organic cation transporterNon-inhibitor0.8276
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6431
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8588
Ames testNon AMES toxic0.5982
CarcinogenicityNon-carcinogens0.7712
BiodegradationNot ready biodegradable0.9834
Rat acute toxicity2.4930 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7097
hERG inhibition (predictor II)Non-inhibitor0.5167
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SuspensionOphthalmic
SuspensionOphthalmic1 %
Suspension / dropsOphthalmic10 mg/mL
Suspension / dropsOphthalmic
Prices
Unit descriptionCostUnit
Azopt 1% Suspension 15ml Bottle163.11USD bottle
Azopt 1% Suspension 10ml Bottle108.83USD bottle
Azopt 1% eye drops8.05USD ml
Azopt 1 % Suspension3.63USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2080223 No2000-11-072011-04-03Canada
US5240923 No1993-08-312010-08-31Us
US5461081 No1993-04-242013-04-24Us
US6316441 No1999-12-072019-12-07Us
US9044484 No2010-10-302030-10-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point131 °CNot Available
logP-1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.713 mg/mLALOGPS
logP-0.65ALOGPS
logP-0.67ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)8.19ChemAxon
pKa (Strongest Basic)6.78ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.8 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity87.2 m3·mol-1ChemAxon
Polarizability37.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Thiazine is a 6-membered ring consisting of four carbon, one nitrogen and one sulfur atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThienothiazines
Sub ClassNot Available
Direct ParentThienothiazines
Alternative Parents
Substituents
  • Thienothiazine
  • 2,3,5-trisubstituted thiophene
  • Aralkylamine
  • Ortho-thiazine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Thiophene
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63. [PubMed:9541386 ]
  2. DeSantis L: Preclinical overview of brinzolamide. Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29. [PubMed:10665514 ]
  3. Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9. [PubMed:14684332 ]
  4. Boriack-Sjodin PA, Zeitlin S, Chen HH, Crenshaw L, Gross S, Dantanarayana A, Delgado P, May JA, Dean T, Christianson DW: Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. 1998 Dec;7(12):2483-9. [PubMed:9865942 ]
  5. Ilies M, Supuran CT, Scozzafava A, Casini A, Mincione F, Menabuoni L, Caproiu MT, Maganu M, Banciu MD: Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg Med Chem. 2000 Aug;8(8):2145-55. [PubMed:11003159 ]
  6. Iester M: Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008 Sep;2(3):517-23. [PubMed:19668749 ]
  7. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9. [PubMed:14684332 ]
  2. Herkel U, Pfeiffer N: Update on topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol. 2001 Apr;12(2):88-93. [PubMed:11224713 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Low activity.
Gene Name:
CA5A
Uniprot ID:
P35218
Molecular Weight:
34750.21 Da
References
  1. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:46